The purpose of this study was to systematically evaluate the clinical efficacy survival and complications of Rad-p53 combined with TACE in the treatment of hepatocellular carcinoma, and to provide evidence-based medical evidence to improve the clinical outcomes of patients with hepatocellular carcinoma. This evidence concerns the gene TP53 and hepatocellular carcinoma.